← Back to Search

Cancer Vaccine

ATG-101 for Advanced Cancers (PROBE Trial)

Phase 1
Recruiting
Research Sponsored by Antengene Biologics Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Aged at least 18 years as of the date of consent.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year after last patient first dose
Awards & highlights

PROBE Trial Summary

This trialstudies a new drug to treat advanced cancers and a type of lymphoma.

Who is the study for?
This trial is for adults with advanced solid tumors or mature B-cell Non-Hodgkin Lymphomas that have worsened after standard treatment, can't tolerate it, or have no suitable standard options. Participants must be expected to live at least 12 weeks and be in fairly good health (ECOG status 0-1). They should use birth control.Check my eligibility
What is being tested?
The study tests ATG-101, a new potential cancer drug. It's the first time this drug is being tried in humans (Phase I) to see how safe it is and how well it works against certain cancers that are either spreading (metastatic) or cannot be removed by surgery.See study design
What are the potential side effects?
Since ATG-101 is new and this is its first trial in humans, specific side effects aren't known yet. However, participants will be closely monitored for any reactions related to the immune system due to the nature of ATG-101 targeting proteins involved in cancer growth.

PROBE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
I am 18 years old or older.

PROBE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year after last patient first dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year after last patient first dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AEs
DLT (for Dose Escalation Phase only)
SAEs
Secondary outcome measures
DCR
DOR
ORR
+4 more

PROBE Trial Design

1Treatment groups
Experimental Treatment
Group I: Single experimental arm for ATG-101Experimental Treatment1 Intervention
Subjects with advanced or metastatic solid tumors and mature B-NHLs will be enrolled.

Find a Location

Who is running the clinical trial?

Antengene Biologics LimitedLead Sponsor
2 Previous Clinical Trials
204 Total Patients Enrolled

Media Library

ATG-101 (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT04986865 — Phase 1
Non-Hodgkin's Lymphoma Research Study Groups: Single experimental arm for ATG-101
Non-Hodgkin's Lymphoma Clinical Trial 2023: ATG-101 Highlights & Side Effects. Trial Name: NCT04986865 — Phase 1
ATG-101 (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04986865 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are being included in this medical trial?

"Indeed, the research hosted on clinicaltrials.gov indicates that this trial is actively recruiting patients at 4 different sites with a total of 482 participants needed. This study was first posted around December 15th 2021 and most recently edited in November 14th 2022."

Answered by AI

What is the desired outcome of this clinical evaluation?

"As reported by the trial sponsor, Antengene Biologics Limited, this study's primary outcome will be Dose Limiting Toxicity (DLT) and it is to be measured over a one-year period. Additionally, secondary objectives include Disease Control Rate (DCR), Overall Response Rate(ORR), as well as pharmacokinetic evaluation of ATG-101 serum concentrations."

Answered by AI

Is the research team actively seeking additional participants?

"Indeed, the data hosted on clinicaltrials.gov attests that this experimental treatment is actively recruiting patients. This trial was initially published on December 15th 2021 and has since been updated on November 14th 2022. There are 482 vacancies across 4 separate medical centres."

Answered by AI

Are there any serious risks associated with the use of ATG-101?

"The safety of ATG-101 is estimated to be a 1 as this trial has only completed the first stage, which limits available evidence on efficacy and safety."

Answered by AI

In what geographic regions is this scientific inquiry being conducted?

"This research is being conducted at the University of Colorado Hospital in Boulder, Fox Chase Cancer Center located in Philadephia and the esteemed University of California San Francisco. Additionally, there are 4 other locations involved with this study."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
2021. "A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04986865.
~15 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top